Navegando por Palavras-chave "linezolid"
Agora exibindo 1 - 6 de 6
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosActivity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers(Esift Srl, 2008-02-01) Sader, Helio Silva [UNIFESP]; Watters, A. A.; Fritsche, T. R.; Jones, R. N.; JMI Labs; Universidade Federal de São Paulo (UNIFESP); Tufts UnivDaptomycin is a cyclic lipopeptide with potent bactericidal activity against Gram-positive organisms and has been approved by the United States Food and Drug Administration for the treatment of Staphylococcus aureus bacteremia and infectious endocarditis (right-side). We evaluated the activity of daptomycin against bloodstream infection S. aureus strains from 4,799 patients hospitalized in 32 medical centers (12 European countries, Turkey and Israel) with bloodstream infections (BSI) during a 5-year period (2002-2006). Intravenous catheters were the source of infection in 15% of cases, and those strains were analyzed separately. All strains were susceptibility tested by reference broth microdilution methods utilizing calcium supplementation (50 mg/L) when testing daptomycin. Bactericidal activity of daptomycin and vancomycin were evaluated against a subset of 50 randomly selected strains. Daptomycin (MIC (50/90), 0.25/0.5 mg/L), vancomycin (MIC50/90, 1/1 mg/L), and linezolid (MIC50/90, 2/2 mg/L), were highly active (>99.9% susceptibility) against the strains evaluated; and daptomycin was the most potent (lowest MIC90) among these compounds. Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection.
- ItemSomente MetadadadosEmergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis(Elsevier B.V., 2006-04-01) Gales, Ana C. [UNIFESP]; Sader, Hélio S. [UNIFESP]; Andrade, Soraya S. [UNIFESP]; Lutz, L.; Machado, A.; Barth, A. L.; Universidade Federal de São Paulo (UNIFESP); JMI Labs; Hosp ClinWe report the first linezolid-resistant Staphylococcus aureus strain isolated in Brazil. the strain was isolated from a 10-year-old female patient with cystic fibrosis (CF) who received repeated and prolonged courses of low-dose linezolid. the strain belonged to the Brazilian endemic methicillin-resistant S. aureus clone, and the G2576U mutation was identified in domain V of the 23S rRNA. Detection of this mechanism of resistance in a CF patient is very worrisome, as these patients may become a reservoir for further dissemination of resistant strains. Our findings emphasise the importance of optimal dosage of linezolid to prevent the emergence of resistance. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
- ItemSomente MetadadadosEndocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization(Elsevier B.V., 2003-02-01) Andrade-Baiocchi, S.; Tognim, MCB; Baiocchi, Otavio Carvalho Guimarães [UNIFESP]; Sader, H. S.; Universidade Federal de São Paulo (UNIFESP)We report a case of infective endocarditis due to vancomycin-intermediate Staphylococcus aureus (VISA) that did not respond to high doses of vancomycin. Initial vancomycin MIC of the last isolate recovered from blood was 8 1 mug/mL, but could be induced up to 32 mug/mL by consecutive growing with vancomycin. Clinical response was only accomplished when linezolid was included in therapy. (C) 2003 Elsevier Science Inc. All rights reserved.
- ItemSomente MetadadadosLEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)(Elsevier B.V., 2007-11-01) Jones, Ronald N.; Fritsche, Thomas R.; Sader, Helio [UNIFESP]; Ross, James E.; JMI Lab; Tufts Univ; Universidade Federal de São Paulo (UNIFESP)Surveillance for emerging linezolid resistance among commonly occurring Gram-positive pathogens in the United States began with the 2002 ZAAPS program and more recently (2004) expanded as the LEADER program. the 2006 LEADER program processed 5374 strains from 50 medical centers (100 per site) located within the 9 US census regions; species and number tested by broth microdilution (% linezolid susceptible) included Staphylococcus aureus (2913, > 99.9), coagulase-negative staphylococci (CoNSs) (808, 98.4), enterococci (547, 97.4), Streptococcus pneumoniae (546, 100.0), viridans group streptococci (189, 100.0), and beta-hemolytic streptococci (371, 100.0). in addition to 1 linezolid-nonsusceptible S. aureus, 3 strains were daptomycin-nonsusceptible, 4 were quinupristin/dalfopristin-intermediate, 2 were vancomycin-intermediate (vancomycin MIC values, 4 mu g/mL), and all were methicillin-resistant S. aureus. Among the linezolid-resistant isolates (1 S. aureus, 13 CoNSs, 3 Enterococcus faecalis, and 10 Enterococcus faecium isolates), all but 3 Staphylococcus epidermidis isolates had the G2567T mutation. Overall, 99.55% of the tested 2006 LEADER program isolates remained susceptible to linezolid at current Clinical and Laboratory Standards Institute breakpoints. (C) 2007 Elsevier Inc. All rights reserved.
- ItemSomente MetadadadosOxazolidinone susceptibility patterns for 2005: International report from the Zyvox (R) Annual Appraisal of Potency and Spectrum study(Elsevier B.V., 2007-03-01) Ross, James E.; Fritsche, Thomas R.; Sader, Helio S. [UNIFESP]; Jones, Ronald N.; JMI Labs; Universidade Federal de São Paulo (UNIFESP); Tufts UnivThe international (non-USA) ZAAPS Program has accumulated 4 years of linezolid resistance surveillance results tracking infections caused by organisms with evolving resistance profiles. the major organism groups monitored were: Staphylococcus aureus and coagulase-negative staphylococci (including methicillin [oxacill in] -resistant strains), enterococci (including vancomycin-resistant [VRE] strains), Streptococcus pneumoniae (including multidrug-resistant [MDR] strains), viridans group streptococci and P-haemolytic streptococci (4209 isolates overall). No linezolid-resistant strains were detected from the 16 monitored nations participating in 2005, consistent with previously reported 2002-2004 results. Linezolid remains highly active against Gram-positive strains including MRSA (MIC90, 2mg/L). With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
- ItemSomente MetadadadosZyvox (R) Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries(Elsevier B.V., 2007-10-01) Jones, Ronald N.; Fritsche, Thomas R.; Sader, Helio S. [UNIFESP]; Ross, James E.; JMI Labs; Tufts Univ; Universidade Federal de São Paulo (UNIFESP)The Zyvox (R) Annual Appraisal of Potency and Spectrum Program has completed its fifth year of monitoring for emerging resistance to linezolid and other Gram-positive active agents on the continents of Europe, Asia, Australia, and Latin America. in 2006, 4216 Gram-positive isolates from 16 nations were submitted for analysis from 6 organism groups including Staphylococcus aureus (54.0%), coagulase-negative staphylococci (CoNS) (14.6%), enterococci (10.0%), Streptococcus pneumoniae (9.4%), viridans group streptococci (5.0%), and beta-hemolytic streptococci (7.0%). Linezolid retained potent activity against S. aureus MIC50 and MIC90, 2 mu g/mL; 39.8% methicillin resistant) and CoNS (MIC50 and MIC90, I mu g/mL; 74.3% methicillin resistant). Despite endemicity of vancomycin-resistant enterococci (up to 30.0%) in several nations, linezolid inhibited >99% of strains at <= 2 mu g/mL (modal MIC, 1 mu g/mL). Among streptococci, all linezolid MIC values were <= 2 mu g/mL. Rare instances of linezolid-resistance were detected in enterococci (2 isolates, China and Germany) and CoNS (3 isolates, Italy and Brazil); 2 CoNS and 1 Enterococcusfiaecium had documented G2576T mutations. Overall, linezolid remained active against 99.88% of tested strains from this global collection. (C) 2007 Elsevier Inc. All rights reserved.